ArticleImmunity, inflammation and disease2026
Methotrexate Modulates Polymorphonuclear Neutrophil Function Through Reduced Chemotaxis and Increased LOX-1 Expression.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethotrexate (MTX) is commonly used in patients with autoimmune disorders with the therapeutic objective of inducing immunosuppression predominantly through the modulation of T-lymphocyte activity. Additional studies suggest that the regulation of polymorphonuclear neutrophils (PMNs) may also play a significant role in disease modification. However, the molecular mechanism underlying this effect remains incompletely understood. Moreover, most studies investigating the interaction between MTX and PMNs have relied on centrifugation for cell isolation, a method meanwhile known to alter PMN behavior and activation status itself.
objectivesThe aim of the study was to investigate the effects of MTX on PMN function-including reactive oxygen species (ROS) production, NETosis (Neutrophil Extracellular Traps), and migration-using live-cell imaging, as well as surface epitopes and the respiratory burst assessed by flow cytometry. This comprehensive set of experiments examining the interaction between MTX and PMNs provides a previously unreported level of insight.
methodsPMNs from healthy donors were isolated using a sedimentation procedure with 10% Gelafundin and subsequently incubated with 0, 0.005, 0.5, or 5 mmol/L MTX for downstream experiments. Live-cell imaging was used to assess neutrophil migration, NETosis, and ROS production, while flow cytometry was conducted to evaluate the activation markers CD11b, CD66b, and CD62L, as well as the surface marker LOX-1 (lectin-type oxidized LDL receptor-1) and ROS production.
resultsLive-cell imaging demonstrated a significant inhibition of chemotactic PMN migration at all MTX concentrations compared to controls. In contrast, neither ROS production nor NETosis could be detected under the same conditions. Flow cytometric analysis revealed a significant upregulation of LOX-1 surface expression, while the activation markers CD11b, CD62L, and CD66b remained unaltered. Furthermore, an increase in ROS production during the respiratory burst could not be detected.
conclusionThese results indicate that MTX reduces the chemotaxis of most naive PMNs. In addition, MTX appears to induce an upregulation of LOX-1. Future studies should further investigate the impact of LOX-1 on PMN function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.